BioWorld covered Nexo’s emergence from stealth, its $60 million financing and the company’s ambition to translate chemistry and chemical biology into programs against elusive cancer targets. […]
Leer más… from BioWorld: Nexo emerges with $60M series A, takes aim at ‘elusive’ targets
MedCity News covered Nexo’s launch, financing and research alliance with MD Anderson, emphasizing the company’s strategy to broaden the amino acids addressable by covalent chemistry. […]
Leer más… from MedCity News: Bio Startup Nexo Lands $60M to Climb to New Heights in Cancer Drug R&D
Pharmaceutical Technology reported on Nexo’s Series A financing and described how the company’s platform combines covalent ligand discovery and chemical biology to pursue previously difficult oncology targets. […]
C&EN highlighted Nexo’s $60 million Series A financing and its effort to apply covalent chemistry to cancer targets that have been difficult to drug with conventional approaches. […]
Leer más… from C&EN: Nexo launches with oncology drug discovery program
BioPharma Dive reported on Nexo’s financing and five-year MD Anderson partnership, framing the company as part of a new wave of startups bringing a more deliberate approach to covalent drug design. […]
Leer más… from BioPharma Dive: Nexo allies with MD Anderson in pursuit of covalent cancer drugs
Nexo Therapeutics launched with $60 million in Series A funding led by Versant Ventures and outlined a platform designed to discover covalent drugs against previously intractable cancer targets. […]
Leer más… from Nexo Therapeutics Launches With $60 Million Series A Financing
MD Anderson and Nexo Therapeutics announced a multi-year collaboration that combines Nexo’s discovery platform with MD Anderson’s TRACTION capabilities to move new small-molecule cancer therapies toward the clinic. […]